DE69531044D1 - Behandlung von entzündung durch die gabe von spezifischen sulfatase-enzymen und/oder inhibitoren der sulfatierung - Google Patents

Behandlung von entzündung durch die gabe von spezifischen sulfatase-enzymen und/oder inhibitoren der sulfatierung

Info

Publication number
DE69531044D1
DE69531044D1 DE69531044T DE69531044T DE69531044D1 DE 69531044 D1 DE69531044 D1 DE 69531044D1 DE 69531044 T DE69531044 T DE 69531044T DE 69531044 T DE69531044 T DE 69531044T DE 69531044 D1 DE69531044 D1 DE 69531044D1
Authority
DE
Germany
Prior art keywords
sulfation
ignition
inhibitors
treatment
sulfatase enzymes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69531044T
Other languages
English (en)
Other versions
DE69531044T2 (de
Inventor
Steven D Rosen
Stefan Hemmerich
Yasuyuki Imai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE69531044D1 publication Critical patent/DE69531044D1/de
Application granted granted Critical
Publication of DE69531044T2 publication Critical patent/DE69531044T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06014—N-Acetylglucosamine-6-sulfatase (3.1.6.14)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69531044T 1994-03-16 1995-03-15 Behandlung von entzündung durch die gabe von spezifischen sulfatase-enzymen und/oder inhibitoren der sulfatierung Expired - Fee Related DE69531044T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21494794A 1994-03-16 1994-03-16
PCT/US1995/003276 WO1995024920A1 (en) 1994-03-16 1995-03-15 Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor

Publications (2)

Publication Number Publication Date
DE69531044D1 true DE69531044D1 (de) 2003-07-17
DE69531044T2 DE69531044T2 (de) 2003-12-04

Family

ID=22801032

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69531044T Expired - Fee Related DE69531044T2 (de) 1994-03-16 1995-03-15 Behandlung von entzündung durch die gabe von spezifischen sulfatase-enzymen und/oder inhibitoren der sulfatierung

Country Status (6)

Country Link
EP (1) EP0750511B1 (de)
JP (1) JPH10500939A (de)
AU (1) AU700369B2 (de)
CA (1) CA2185324A1 (de)
DE (1) DE69531044T2 (de)
WO (1) WO1995024920A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515708A1 (en) * 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
WO2007109851A1 (en) 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
WO2008119109A1 (en) 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
WO2010022461A1 (en) * 2008-08-29 2010-03-04 Children, Youth And Women's Health Service Sulphated sugars to increase activity of sulphatases en lysosomal storage disorders
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
EP3830139A4 (de) * 2018-07-27 2022-04-27 Arc Medical Devices, Inc. Hochgereinigte fucane zur behandlung von faserigen adhäsionen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512977A (en) * 1979-10-18 1985-04-23 Lundy Research Laboratories, Inc. Therapeutic selenium compositions and the use thereof
AU4859793A (en) * 1992-09-11 1994-04-12 Regents Of The University Of California, The Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
AU1255695A (en) * 1993-11-19 1995-06-06 Regents Of The University Of California, The Sulfated ligands for l-selectin and methods of preventing sulfate addition

Also Published As

Publication number Publication date
CA2185324A1 (en) 1995-09-21
WO1995024920A1 (en) 1995-09-21
JPH10500939A (ja) 1998-01-27
AU2120995A (en) 1995-10-03
AU700369B2 (en) 1999-01-07
EP0750511A1 (de) 1997-01-02
EP0750511B1 (de) 2003-06-11
DE69531044T2 (de) 2003-12-04
EP0750511A4 (de) 1999-05-06

Similar Documents

Publication Publication Date Title
DE3853558D1 (de) Behandlung von Hyperhidrose und Ichtyosis.
ATE131068T1 (de) Behandlung von pathologischen zuständen und krankheiten.
BR9407799A (pt) Composição de matéria método de tratamento e composição farmaceutica
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
DE59911005D1 (de) Aminosäureester von arylsulfonamiden und analoga
DE69530597D1 (de) Behandlung von Obst und Gemüse
DE69014030D1 (de) Mittel für die Verhütung und Behandlung von Diarrhöe.
DE69426690D1 (de) Behandlung von atrophischer Haut und Vagina
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
DE69316203D1 (de) Elektrochemische behandlung von oberflächen
DE3670310D1 (de) Elektrochemische behandlung von ligninen.
KR880700673A (ko) 골손상 치료용방법 및 조성물
DE69132032D1 (de) Verzögerung, verhinderung und/oder rückgängigmachen von zellalterung
DE69531044D1 (de) Behandlung von entzündung durch die gabe von spezifischen sulfatase-enzymen und/oder inhibitoren der sulfatierung
DE3850433D1 (de) Allergiebehandlung und Zusammensetzung dafür.
DE69841550D1 (de) Behandlung von fibromyalgie und verwandten erkrankungen
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
DE3680881D1 (de) Behandlung von hologrammen.
DE68923219D1 (de) Behandlung von Abfällen.
DE59813914D1 (de) Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
DE3881377D1 (de) Mittel zur prophylaxe und behandlung von thrombocytopenie.
DE3855561D1 (de) Mittel zur verhütung von zahnbelag und belagabhängigen krankheiten
FR2598082B1 (fr) Agent prophylactique et therapeutique de traitement de desordres hepatiques

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee